1[1]Bymaster FP,Calligaro DO,Falcone JF,et al.Radioreceptor binding profile of the atypical antipsychotic olanzapine.Neuropsychopharmacology ,1996,14:87
2[2]Kapur S,Zipursky RB,Remington G,et al.Clinical and theor etical implications of 5-HT2 and D2 receptor occupancy of clozapine,risperi dole,and olanzapine in schizophreia.Am J Psychiatry,1999,156:286
3[3]Arnt J,Skarsfeldt J.Do noval antipsychotics have similar pharmacological characteristics?a review of the evidence.Neuropsychopharmacolog y,1998,16:63
4[4]Bymaster FP.In vivo and in vitro biochemistry of olanzap ine.J Clin Psychiatry,1997,58(suppl 10):28
5[5]Tandon R,Milner K,Jibson MD.Antipsychotics from theory t o practice:integrating clinical and basic data.J Clin Psychiatry,1999,60(suppl 8 ):21
6[6]Beasley CM,Tollefson GD,Tran PV,et al.The efficacy of ol anzapine:the summary of global,multicentral clinical trials.J Clin Psychiatry,19 97,58(suppl 10):7
7[7]Sanger TM,Lieberman JA,Tohen M,et al.Olanzapine versus h aloperidol treatment in first-episode psychosis.Am J Psychiatry,1999,156:79
8[8]Tran PV,Hamilton SH,Runtz AJ,et al.Double-blind compari son of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.J Clin Psychopharmacol,1997,17:407
9[9]Brier A,Hamilton SH.Comparative efficacy olanzapine and haloperidol for patients with treatmen-resistant schizophrenia.Biol Psychiatry,45:403
10[10] Henderson DC,Nasrallah RA,Goff DC,et al.Switching from clozapin e to olanzapine in treatment-resistant schizophrenia:safety clinical effecacy,a nd predictors of response.J Clin Psychiatry,1998,59:585
